GlassScriptPhysician profile
Roshmoti L Wolfe
NPI 1790210458
$1,024.43
in general payments reported to CMS, 2019-2025
10 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $453 · 2022: $175 · 2023: $49.20 · 2024: $42.99 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $326.00 | 2021-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $192.51 | 2021 | |
| Corium, LLC | $151.29 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.40 | 2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $64.22 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $57.52 | 2021-2025 | Abilify Asimtufii, Abilify Maintena |
| Collegium Pharmaceutical, INC. | $47.45 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $29.83 | 2025 | Auvelity |
| Tris Pharma INC | $26.54 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshmoti Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.